GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

The global progressive pulmonary fibrosis (PPF) treatment market is projected to be valued at USD 4,044.6 Million in 2025 and is expected to reach USD 8,182.4 Million by 2035, registering a CAGR of 7.

The Global Alcohol-Related Liver Disease Market report for 2025-2035 highlights the escalating trend of alcohol-related liver conditions like alcoholic fatty liver disease (AFLD), alcoholic hepatitis, ...

London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

Results come after positive results from a trial among people with idiopathic pulmomary disease.

This study reveals that neutrophil extracellular traps (NETs) drive macrophage-derived chemokine production (CXCL9/10/11) to promote CD8+ T cell ...

"Cannabis use has been linked to an increased risk of cardiopulmonary disease and psychiatric conditions such as psychosis, anxiety, depression, and suicidal ideation," they wrote.

Preclinical study results provide a comprehensive transcriptomic characterization of regenerative wound repair in the oral mucosa.